Christopher Kim, MD
Vascular & Interventional Radiology · Galloway, NJNPI 1962757690
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Boston Scientific at 44.3% of the total.
Across 55 payments — averaging $70.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Cardiovascular Systems Inc.$516
- Bard Peripheral Vascular, Inc.$516
- Abbott$395
- Terumo Medical Corporation$327
- Penumbra, Inc.$150
- plus $241 from 6 others
Across 7 payments — averaging $1874.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merit Medical Systems Inc$13K
What the payments were for
- Grants$211%
- Food & beverage$3,83199%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 23 | $1,706 |
| Cardiovascular Systems Inc. | 9 | $516 |
| Bard Peripheral Vascular, Inc. | 7 | $516 |
| Abbott | 6 | $395 |
| Terumo Medical Corporation | 3 | $327 |
| Penumbra, Inc. | 1 | $150 |
| UCB, Inc. | 1 | $125 |
| GE HealthCare | 1 | $36 |
| W. L. Gore & Associates, Inc. | 1 | $24 |
| AbbVie | 1 | $21 |
| Cardinal Health 200 LLC | 1 | $18 |
| Medtronic | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELUVIA$319
- Supera peripheral stent system$258
- GENERAL ANGIOPLASTY$250
- Peripheral Orbital Atherectomy System$226
- Azur CX Detachable$158
- Navicross$158
- HydroPearl$158
- Indigo System$150
- TheraSphere Y90 Glass Microspheres 10 GBq$148
- GENERAL VASCULAR INTERVENTION$130
- COVERA$127
- LUTONIX$127
- Nayzilam$125
- ROTALINK$117
- RotarexS 6 F x 135 cm$115
How this compares
$3,851 in reported general payments places this provider in the 65th percentile of 111 vascular & interventional radiology providers in New Jersey.
See all vascular & interventional radiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 19 | $83 |
Paid to pharmacies, not to this prescriber.
Other vascular & interventional radiology in Galloway
- Nicholas PetruzziGalloway$407K
- Micah WattsGalloway$225K
- Bridgette McCabeGalloway$7K
- John di CapuaGalloway$4K
- Michael SchmidlingGalloway$3K
- John RundbackTeaneck$507K
- Sabina AminCamden$346K
- Israel SchurClifton$247K
- Kevin HermanTeaneck$154K
- Elsie KohWoodland Park$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.